The beneficial impact of detection of a CD8+ T cell response to candidate tumor antigens on relapse risk and RFS is still observed, with adjustment for time to start of AZA therapy (HR, .30; 95% CI, .1 to .94; P = .039) or if restricted to only 24 patients who commenced AZA before day +90 after transplantation (HR, .32; 95% CI, .10 to .95; P = .041) in the competing risk analysis. Here, CD8A is linked to neoplasm.